Abiopharma

🔍 Elkins David V (Executive)

Company: BRISTOL MYERS SQUIBB CO (BMY)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Sold 25,519 shares of Common Stock, $0.10 par value at $61.6 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 163,729.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,481 shares of Common Stock, $0.10 par value at $62.05 per share (Direct)
  Date: 2026-04-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 159,248.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock, $0.10 par value (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: BMS Savings and Investment Program | shares_owned_after: 294.42 | Footnotes: F4

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.
• F2: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
• F3: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
• F4: Based on recent 401(k) plan statement.